Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474

Endocrine-Related Cancer

Volumn 16, Issue 1, 2009, Pages 233-241

  Carlomagno, Francesca ^a   Guida, Teresa ^a   Anaganti, Suresh ^a   Provitera, Livia ^a   Kjaer, Svend ^b   McDonald, Neil Q ^b   Ryan, Anderson J ^c   Santoro, Massimo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHENYLALANINE; PROTEIN RET; TRANSCRIPTION FACTOR AP 1; TYROSINE; VANDETANIB; DRUG DERIVATIVE; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 ((1 METHYLPIPERIDIN 4 YL)METHOXY)QUINAZOLIN 4 AMINE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RET PROTEIN, HUMAN; TYROSINAMIDE;

AMINO ACID SUBSTITUTION; ARTICLE; AUTOPHOSPHORYLATION; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; GENE MUTATION; HELA CELL; HUMAN; HUMAN CELL; NEUROFIBROMATOSIS; NUCLEOTIDE BINDING SITE; PROMOTER REGION; PROTEIN PHOSPHORYLATION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; THYROID CARCINOMA; AMINO ACID SEQUENCE; CHEMISTRY; CYTOLOGY; DRUG RESISTANCE; GENETICS; KIDNEY; METABOLISM; MOLECULAR GENETICS; NEOPLASM; PROTEIN TERTIARY STRUCTURE; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; DRUG RESISTANCE, NEOPLASM; HELA CELLS; HUMANS; KIDNEY; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NEOPLASMS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-RET; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; TYROSINE;

EID: 65549139324     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0213     Document Type: Article

References (32)

1. Baselga J 2006 Targeting tyrosine kinases in cancer: the second wave. Science 312 1175-1178.
2. Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J et al. 2005 Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nature Genetics 37 1315-1316.
3. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A & Santoro M 2002 ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Research 62 7284-7290.
4. Carlomagno F, Vitagliano D, Guida T, Basolo F, Castellone MD, Melillo RM, Fusco A & Santoro M 2003 Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo [3,4-d]pyrimidine (PP2). Journal of Clinical Endocrinology and Metabolism 88 1897-1902.
5. Carlomagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, Billaud M & Santoro M 2004 Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23 6056-6063.
6. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, Shiraga S, Bainbridge T, Morich J & Heinrich MC 2005 PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. Journal of Clinical Oncology 23 5357-5364.
7. Cranston AN, Carniti C, Oakhill K, Radzio-Andzelm E, Stone EA, McCallion AS, Hodgson S, Clarke S, Mondellini P, Leyland J et al. 2006 RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. Cancer Research 66 10179-10187.
8. Daub H, Specht K & Ullrich A 2004 Strategies to overcome resistance to targeted protein kinase inhibitors. Nature Reviews. Drug Discovery 3 1001-1010.
9. Hayashi H, Ichihara M, Iwashita T, Murakami H, Shimono Y, Kawai K, Kurokawa K, Murakumo Y, Imai T, Funahashi H et al. 2000 Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 19 4469-4475.
10. Iwashita T, Murakami H, Kurokawa K, Kawai K, Miyauchi A, Futami H, Qiao S, Ichihara M & Takahashi M 2000 A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations. Biochemical and Biophysical Research Communications 268 804-808.
11. Kantasjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mieflowski W et al. 2006 Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. New England Journal of Medicine 354 2542-2551.
12. Kawamoto Y, Takeda K, Okuno Y, Yamakawa Y, Ito Y, Taguchi R, Kato M, Suzuki H, Takahashi M & Nakashima I 2004 Identification of RET autophosphorylation sites by mass spectrometry. Journal of Biological Chemistry 279 14213-14224.
13. Knowles PP, Murray-Rust J, Kjaer S, Scott RP, Hanrahan S, Santoro M, Ibáñez CF & McDonald NQ 2006 Structure and chemical inhibition of the RET tyrosine kinase domain. Journal of Biological Chemistry 281 33577-33587.
14. Krause DS & Van Etten RA 2005 Tyrosine kinases as targets for cancer therapy. New England Journal of Medicine 353 172-187.
15. Marx SJ 2005 Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nature Reviews. Cancer 5 367-375.
16. Miyauchi A, Futami H, Hai N, Yokozawa T, Kuma K, Aoki N, Kosugi S, Sugano K & Yamaguchi K 1999 Two germline missense mutations at codons 804 and 806 of the RET prolo-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Japanese Journal of Cancer Research 90 1-5.
17. Nardi V, Azam M & Daley GQ 2004 Mechanisms and implications of Imatinib resistance mutations in BCRABL. Current Opinion in Hematology 11 35-43.
18. O'Hare T, Corbin AS & Druker BJ 2006 Targeted CML therapy: controlling drug resistance, seeking cure. Current Opinion in Genetics & Development 16 92-99.
19. Oriola J, Halperin J, Rivera-Fillat F & Donis-Keller H 2002 The finding of a somatic deletion in RET exon 15 clarified the sporadic nature of a medullary thyroid carcinoma suspected to be familial. Journal of Endocrinological Investigation 25 25-31.
20. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG & Varmus H 2005 Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Medicine 2 e73.
21. Ryan AJ & Wedge SR 2005 ZD6474 - a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. British Journal of Cancer 92 S6-S13.
22. Salvatore D, Barone MV, Salvatore G, Melillo RM, Chiappetta G, Mineo A, Fenzi G, Vecchio G, Fusco A & Santoro M 2000 Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins. Journal of Clinical Endocrinology and Metabolism 85 3898-3907.
23. Santoro M & Carlomagno F 2006 Drug insight: smallmolecule inhibitors of protein kinases in the treatment of thyroid cancer. Nature Clinical Practice. Endocrinology & Metabolism 2 42-52.
24. Santoro M, Wong WT, Aroca P, Santos E, Matoskova B, Grieco M, Fusco A & di Fiore PP 1994 An epidermal growth factor receptor/ret chimera generates mitogenic and transforming signals: evidence for a ret-specific signaling pathway. Molecular and Cellular Biology 14 663-675.
25. Schlumberger M, Carlomagno F, Baudin E, Bidart JM & Santoro M 2008 New therapeutic approaches to treat medullary thyroid carcinoma. Nature Clinical Practice. Endocrinology & Metabolism 4 22-32.
26. Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL & Sawyers CL 2007 Sequential ABL kinase inhibitor therapy selects for compound drugresistant BCR-ABL mutations with altered oncogenic potency. Journal of Clinical Investigation 117 2562-2569.
27. Sherbenou DW & Druker BJ 2007 Applying the discovery of the Philadelphia chromosome. Journal of Clinical Investigation 117 2067-2074.
28. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E et al. 2006 Dasatinib in Imatinib-resistant Philadelphia chromosome-positive leukemias. New England Journal of Medicine 354 2531-2541.
29. Uchino S, Noguchi S, Yamashita H, Sato M, Adachi M, Yamashita H, Watanabe S, Ohshima A, Mitsuyarna S, Iwashita T et al. 1999 Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type. Japanese Journal of Cancer Research 90 1231-1237.
30. Vidal M, Wells S, Ryan A & Cagan R 2005 ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma. Cancer Research 65 3538-3541.
31. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A & Griffin JD 2007 Second generation inhibitors of BCRABL for the treatment of Imatinib-resistant chronic myeloid leukaemia. Nature Reviews. Cancer 7 345-356.
32. Wells S, You YN, Lakhani V, Hou J, Langmuir P, Headley D, Skinner M, Morse M, Burch W & Schlumberger M 2006 A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer. Journal of Clinical Oncology 24 5533 (ASCO Annual Meeting Proceedings Part I).